Cyteir Therapeutics, Inc.

NASDAQ:CYT

3.02 (USD) • At close March 15, 2024
Bedrijfsnaam Cyteir Therapeutics, Inc.
Symbool CYT
Munteenheid USD
Prijs 3.02
Beurswaarde 108,714,262
Dividendpercentage 0%
52-weken bereik 1.65 - 3.19
Industrie Biotechnology
Sector Healthcare
CEO Dr. Markus F. Renschler M.D.
Website https://cyteir.com

An error occurred while fetching data.

Over Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in

Vergelijkbare Aandelen

Curis, Inc. logo

Curis, Inc.

CRIS

5.86 USD

LifeMD, Inc. logo

LifeMD, Inc.

LFMD

5.24 USD

Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc.

VRCA

1.85 USD

Movano Inc. logo

Movano Inc.

MOVE

0.36 USD

Lumos Pharma, Inc. logo

Lumos Pharma, Inc.

LUMO

3.7 USD

Mustang Bio, Inc. logo

Mustang Bio, Inc.

MBIO

0.254 USD

ImmuCell Corporation logo

ImmuCell Corporation

ICCC

3.6 USD

Neuronetics, Inc. logo

Neuronetics, Inc.

STIM

0.945 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)